These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 31396225)

  • 21. A dynamic in vivo-like organotypic blood-brain barrier model to probe metastatic brain tumors.
    Xu H; Li Z; Yu Y; Sizdahkhani S; Ho WS; Yin F; Wang L; Zhu G; Zhang M; Jiang L; Zhuang Z; Qin J
    Sci Rep; 2016 Nov; 6():36670. PubMed ID: 27830712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Role of Microglia in Brain Metastases: Mechanisms and Strategies.
    Feng Y; Hu X; Zhang Y; Wang Y
    Aging Dis; 2024 Feb; 15(1):169-185. PubMed ID: 37307835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases.
    Arvanitis CD; Ferraro GB; Jain RK
    Nat Rev Cancer; 2020 Jan; 20(1):26-41. PubMed ID: 31601988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of breast cancer cells´ secretome on the brain metastatic niche remodeling.
    Carvalho R; Paredes J; Ribeiro AS
    Semin Cancer Biol; 2020 Feb; 60():294-301. PubMed ID: 31711993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brain Tumor Microenvironment and Host State: Implications for Immunotherapy.
    Tomaszewski W; Sanchez-Perez L; Gajewski TF; Sampson JH
    Clin Cancer Res; 2019 Jul; 25(14):4202-4210. PubMed ID: 30804019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor microenvironment differences between primary tumor and brain metastases.
    Cacho-Díaz B; García-Botello DR; Wegman-Ostrosky T; Reyes-Soto G; Ortiz-Sánchez E; Herrera-Montalvo LA
    J Transl Med; 2020 Jan; 18(1):1. PubMed ID: 31900168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions.
    Pansy K; Uhl B; Krstic J; Szmyra M; Fechter K; Santiso A; Thüminger L; Greinix H; Kargl J; Prochazka K; Feichtinger J; Deutsch AJ
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance.
    Owyong M; Hosseini-Nassab N; Efe G; Honkala A; van den Bijgaart RJE; Plaks V; Smith BR
    Drug Resist Updat; 2017 Nov; 33-35():23-35. PubMed ID: 29145972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microglia and metastases to the central nervous system: victim, ravager, or something else?
    Caffarel MM; Braza MS
    J Exp Clin Cancer Res; 2022 Nov; 41(1):327. PubMed ID: 36411434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Evolving Modern Management of Brain Metastasis.
    Fecci PE; Champion CD; Hoj J; McKernan CM; Goodwin CR; Kirkpatrick JP; Anders CK; Pendergast AM; Sampson JH
    Clin Cancer Res; 2019 Nov; 25(22):6570-6580. PubMed ID: 31213459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of the systemic immune system in brain metastasis.
    Hamilton A; Sibson NR
    Mol Cell Neurosci; 2013 Mar; 53():42-51. PubMed ID: 23073146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunological Consequences of Epithelial-Mesenchymal Transition in Tumor Progression.
    Chockley PJ; Keshamouni VG
    J Immunol; 2016 Aug; 197(3):691-8. PubMed ID: 27431984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salting the Soil: Targeting the Microenvironment of Brain Metastases.
    Srinivasan ES; Tan AC; Anders CK; Pendergast AM; Sipkins DA; Ashley DM; Fecci PE; Khasraw M
    Mol Cancer Ther; 2021 Mar; 20(3):455-466. PubMed ID: 33402399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
    Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
    Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic tumor microenvironment targeting and blood-brain barrier penetration via a pH-responsive dual-ligand strategy for enhanced breast cancer and brain metastasis therapy.
    Li M; Shi K; Tang X; Wei J; Cun X; Long Y; Zhang Z; He Q
    Nanomedicine; 2018 Aug; 14(6):1833-1843. PubMed ID: 29800759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microenvironmental Heterogeneity in Brain Malignancies.
    Perus LJM; Walsh LA
    Front Immunol; 2019; 10():2294. PubMed ID: 31632393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The immunosuppressive microenvironment of malignant gliomas].
    Borisov KE; Sakaeva DD
    Arkh Patol; 2015; 77(6):54-63. PubMed ID: 26841651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glioblastoma Chemoresistance: The Double Play by Microenvironment and Blood-Brain Barrier.
    Da Ros M; De Gregorio V; Iorio AL; Giunti L; Guidi M; de Martino M; Genitori L; Sardi I
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30248992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Biology of Brain Metastasis: Challenges for Therapy.
    Fidler IJ
    Cancer J; 2015; 21(4):284-93. PubMed ID: 26222080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppressing immunotherapy by organ-specific tumor microenvironments: what is in the brain?
    Zhang C; Yu D
    Cell Biosci; 2019; 9():82. PubMed ID: 31624532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.